FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170463669> ?p ?o ?g. }

• W2170463669 endingPage "1258" @default.
• W2170463669 startingPage "1250" @default.
• W2170463669 abstract "The emergence and spread of high levels of HIV-1 drug resistance in resource-limited settings where combination antiretroviral treatment has been scaled up could compromise the effectiveness of national HIV treatment programmes. We aimed to estimate changes in the prevalence of HIV-1 drug resistance in treatment-naive individuals with HIV since initiation of rollout in resource-limited settings.We did a systematic search for studies and conference abstracts published between January, 2001, and July, 2011, and included additional data from the WHO HIV drug resistance surveillance programme. We assessed the prevalence of drug-resistance mutations in untreated individuals with respect to time since rollout in a series of random-effects meta-regression models.Study-level data were available for 26,102 patients from sub-Saharan Africa, Asia, and Latin America. We recorded no difference between chronic and recent infection on the prevalence of one or more drug-resistance mutations for any region. East Africa had the highest estimated rate of increase at 29% per year (95% CI 15 to 45; p=0·0001) since rollout, with an estimated prevalence of HIV-1 drug resistance at 8 years after rollout of 7·4% (4·3 to 12·7). We recorded an annual increase of 14% (0% to 29%; p=0·054) in southern Africa and a non-significant increase of 3% (-0·9 to 16; p=0·618) in west and central Africa. There was no change in resistance over time in Latin America, and because of much country-level heterogeneity the meta-regression analysis was not appropriate for Asia. With respect to class of antiretroviral, there were substantial increases in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) in east Africa (36% per year [21 to 52]; p<0·0001) and southern Africa (23% per year [7 to 42]; p=0·0049). No increase was noted for the other drug classes in any region.Our findings suggest a significant increase in prevalence of drug resistance over time since antiretroviral rollout in regions of sub-Saharan Africa; this rise is driven by NNRTI resistance in studies from east and southern Africa. The findings are of concern and draw attention to the need for enhanced surveillance and drug-resistance prevention efforts by national HIV treatment programmes. Nevertheless, estimated levels, although increasing, are not unexpected in view of the large expansion of antiretroviral treatment coverage seen in low-income and middle-income countries--no changes in antiretroviral treatment guidelines are warranted at the moment.Bill & Melinda Gates Foundation and the European Community's Seventh Framework Programme." @default.
• W2170463669 created "2016-06-24" @default.
• W2170463669 creator A5017146733 @default.
• W2170463669 creator A5023187202 @default.
• W2170463669 creator A5033619221 @default.
• W2170463669 creator A5036869978 @default.
• W2170463669 creator A5052083685 @default.
• W2170463669 creator A5054490440 @default.
• W2170463669 creator A5058706123 @default.
• W2170463669 creator A5059988483 @default.
• W2170463669 creator A5060462160 @default.
• W2170463669 creator A5077500073 @default.
• W2170463669 creator A5080859236 @default.
• W2170463669 date "2012-10-01" @default.
• W2170463669 modified "2023-10-03" @default.
• W2170463669 title "Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis" @default.
• W2170463669 cites W146845631 @default.
• W2170463669 cites W1731654638 @default.
• W2170463669 cites W2015804617 @default.
• W2170463669 cites W2024161781 @default.
• W2170463669 cites W2029246165 @default.
• W2170463669 cites W2040350327 @default.
• W2170463669 cites W2045871034 @default.
• W2170463669 cites W2061035596 @default.
• W2170463669 cites W2063358293 @default.
• W2170463669 cites W2074001132 @default.
• W2170463669 cites W2081095866 @default.
• W2170463669 cites W2087683730 @default.
• W2170463669 cites W2096686776 @default.
• W2170463669 cites W2097245338 @default.
• W2170463669 cites W2105978365 @default.
• W2170463669 cites W2109046728 @default.
• W2170463669 cites W2118380757 @default.
• W2170463669 cites W2120293408 @default.
• W2170463669 cites W2128879707 @default.
• W2170463669 cites W2133166320 @default.
• W2170463669 cites W2148361291 @default.
• W2170463669 cites W2149573022 @default.
• W2170463669 cites W2152896082 @default.
• W2170463669 cites W2170578204 @default.
• W2170463669 cites W2216916698 @default.
• W2170463669 cites W2308294549 @default.
• W2170463669 doi "https://doi.org/10.1016/s0140-6736(12)61038-1" @default.
• W2170463669 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3790969" @default.
• W2170463669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22828485" @default.
• W2170463669 hasPublicationYear "2012" @default.
• W2170463669 type Work @default.
• W2170463669 sameAs 2170463669 @default.
• W2170463669 citedByCount "326" @default.
• W2170463669 countsByYear W21704636692012 @default.
• W2170463669 countsByYear W21704636692013 @default.
• W2170463669 countsByYear W21704636692014 @default.
• W2170463669 countsByYear W21704636692015 @default.
• W2170463669 countsByYear W21704636692016 @default.
• W2170463669 countsByYear W21704636692017 @default.
• W2170463669 countsByYear W21704636692018 @default.
• W2170463669 countsByYear W21704636692019 @default.
• W2170463669 countsByYear W21704636692020 @default.
• W2170463669 countsByYear W21704636692021 @default.
• W2170463669 countsByYear W21704636692022 @default.
• W2170463669 countsByYear W21704636692023 @default.
• W2170463669 crossrefType "journal-article" @default.
• W2170463669 hasAuthorship W2170463669A5017146733 @default.
• W2170463669 hasAuthorship W2170463669A5023187202 @default.
• W2170463669 hasAuthorship W2170463669A5033619221 @default.
• W2170463669 hasAuthorship W2170463669A5036869978 @default.
• W2170463669 hasAuthorship W2170463669A5052083685 @default.
• W2170463669 hasAuthorship W2170463669A5054490440 @default.
• W2170463669 hasAuthorship W2170463669A5058706123 @default.
• W2170463669 hasAuthorship W2170463669A5059988483 @default.
• W2170463669 hasAuthorship W2170463669A5060462160 @default.
• W2170463669 hasAuthorship W2170463669A5077500073 @default.
• W2170463669 hasAuthorship W2170463669A5080859236 @default.
• W2170463669 hasBestOaLocation W21704636692 @default.
• W2170463669 hasConcept C114851261 @default.
• W2170463669 hasConcept C124936440 @default.
• W2170463669 hasConcept C126322002 @default.
• W2170463669 hasConcept C138885662 @default.
• W2170463669 hasConcept C142462285 @default.
• W2170463669 hasConcept C144024400 @default.
• W2170463669 hasConcept C149923435 @default.
• W2170463669 hasConcept C158886217 @default.
• W2170463669 hasConcept C203014093 @default.
• W2170463669 hasConcept C2778451633 @default.
• W2170463669 hasConcept C2993143319 @default.
• W2170463669 hasConcept C3013748606 @default.
• W2170463669 hasConcept C3019165603 @default.
• W2170463669 hasConcept C41895202 @default.
• W2170463669 hasConcept C71924100 @default.
• W2170463669 hasConcept C86803240 @default.
• W2170463669 hasConcept C89423630 @default.
• W2170463669 hasConcept C95190672 @default.
• W2170463669 hasConcept C99454951 @default.
• W2170463669 hasConceptScore W2170463669C114851261 @default.
• W2170463669 hasConceptScore W2170463669C124936440 @default.
• W2170463669 hasConceptScore W2170463669C126322002 @default.
• W2170463669 hasConceptScore W2170463669C138885662 @default.
• W2170463669 hasConceptScore W2170463669C142462285 @default.

• next